FDA Panel Backs Safety Of AstraZeneca Diabetes Drug

Law360, Los Angeles (April 14, 2015, 10:26 PM EDT) -- A U.S. Food and Drug Administration committee has determined an AstraZeneca PLC diabetes drug is safe after conducting an investigation into a potential link to heart failure found in an earlier study, but it did recommend new labeling be added to the drug, the company announced Tuesday.

The agency had asked AstraZeneca to supply it with clinical trial data in order to examine a possible link between the drugmaker's saxagliptin and heart failure. Saxagliptin is marketed as Onglyza, which was approved by the FDA in July 2009, and Kombiglyze XR, which was approved in November 2010.

On Tuesday, AstraZeneca announced that...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!